PriceTargets.com logo

Traws Pharma - TRAW Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.00
  • Forecasted Upside: 238.98%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.36 As of 12/4/2025 05:00 PM ET
▲ +0.25 (11.85%)

This chart shows the closing price for TRAW by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Traws Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRAW and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRAW

Analyst Price Target is $8.00
▲ +238.98% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Traws Pharma in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 238.98% upside from the last price of $2.36.

This chart shows the closing price for TRAW for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in Traws Pharma. This rating changed within the last month from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/3/2025HC WainwrightInitiated CoverageBuy$8.00
12/3/2025HC WainwrightInitiated CoverageBuy$8.00
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/19/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/30/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 12/5/2020 forward)

News Sentiment Rating

-0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 2 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Traws Pharma logo
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Read More

Today's Range

Now: $2.36
Low: $2.05
High: $2.40

50 Day Range

MA: $2.40
Low: $1.77
High: $3.13

52 Week Range

Now: $2.36
Low: $0.97
High: $19.44

Volume

438,130 shs

Average Volume

594,047 shs

Market Capitalization

$18.86 million

P/E Ratio

0.02

Dividend Yield

N/A

Beta

1.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Traws Pharma?

The following equities research analysts have issued research reports on Traws Pharma in the last twelve months: HC Wainwright, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for TRAW.

What is the current price target for Traws Pharma?

0 Wall Street analysts have set twelve-month price targets for Traws Pharma in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 239.0%. HC Wainwright has the highest price target set, predicting TRAW will reach $8.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Traws Pharma in the next year.
View the latest price targets for TRAW.

What is the current consensus analyst rating for Traws Pharma?

Traws Pharma currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TRAW, but not buy more shares or sell existing shares.
View the latest ratings for TRAW.

What other companies compete with Traws Pharma?

Other companies that are similar to Traws Pharma include PMV Pharmaceuticals, Sutro Biopharma, Estrella Immunopharma, NRx Pharmaceuticals and InflaRx. Learn More about companies similar to Traws Pharma.

How do I contact Traws Pharma's investor relations team?

Traws Pharma's physical mailing address is 12 PENNS TRAIL, NEWTOWN PA, 18940. The company's listed phone number is 267-759-3680 and its investor relations email address is [email protected]. The official website for Traws Pharma is www.onconova.com. Learn More about contacing Traws Pharma investor relations.